President Trump signed an Executive Order to speed up research and approval of psychedelic medications for serious mental illnesses like depression, PTSD, and suicidality. NRx Pharmaceuticals, which is developing NRX-100, a preservative-free ketamine treatment for depression including suicidal ideation, welcomes this move as it aligns with their FDA Fast Track designation and upcoming drug application. The order also encourages collaboration between government agencies and the private sector to use real-world evidence and clinical trials to facilitate drug approvals. This initiative aims to improve treatment options for mental health conditions, especially for veterans and first responders.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
Telo Genomics announced positive interim results from a clinical study analyzing blood samples of multiple myeloma patients to predict relapse risk using 3D telomere analysis. The test showed strong predictive accuracy, potentially offering a less in...
Meta now notifies parents if their teen talks about suicide or self-harm with its AI chatbot and is developing a feature to contact emergency services if risk is detected. This move addresses concerns about AI chatbots handling crisis conversations, ...
Garmin introduced the G2000 PRIME, a new integrated flight deck designed for high-performance Class I/II piston and electric aircraft. It features large, edge-to-edge touchscreen displays with advanced multi-touch capabilities, faster processors, and...
